Michael Barbella, Managing Editor09.11.23
Microbot Medical Inc. has welcomed to its Scientific Advisory Board Irene Bargellini, M.D., an interventional radiologist and chair of the Diagnostic and Interventional Radiology Department at Candiolo Cancer Institute in Turin, Italy.
Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
“It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” Microbot Medical Chief Medical Officer Eyal Morag, M.D., said. “In addition to leveraging Dr. Bargellini’s expertise to achieve this goal, we also recognize that Italy represents an important and potentially large addressable market for the LIBERTY Robotic Surgical System. Dr. Bargellini is a potential future user, who we believe could support our entry into the Italian market upon regulatory clearance.”
Bargellini earned her medical degree from the University of Pisa, completed her radiology residency in Pisa and earned a master's degree in interventional radiology. From 2003 to 2022, she served as staff radiologist in the Interventional Radiology Department of Pisa University Hospital, then worked in the Interventional Radiology Unit of Florence University Hospital and just recently moved to Turin at Candiolo Cancer Institute. The main focus of her clinical and scientific work is oncologic imaging and interventional oncology, with particular reference to liver imaging and liver tumors' loco-regional and systemic therapies.
Bargellini is an Executive Committee member of the Italian Society of Radiology, a fellow of the European Society of Gastrointestinal and Abdominal Radiology and the Cardiovascular and Interventional Radiology Society in Europe, and a member of the European Society of Radiology, European Society for the Study of the Liver, and International Liver Cancer Association. She serves as reviewer of several national and international journals and is an editorial board member of European Radiology and Cardiovascular and Interventional Radiology journals. Bargellini has authored and co-authored more than 100 articles in peer-review journals, is co-author of several book chapters, and has given over 300 invited lectures in national and international meetings.
“I believe it’s important to support technology that can advance medicine and improve patient outcomes, and having experienced the system first-hand, I am eager to lend my capabilities and contribute to the system’s success,” Bargellini stated. “Additionally, I believe the potential of the LIBERTY Robotic Surgical System to reduce the level of radiation exposure makes it possible for more women to pursue a career as interventional radiologists, while not potentially endangering their health and/or ability to have children.”
The LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain.
Microbot Medical Inc. is a pre-clinical medical device company specializing in transformational micro-robotic technologies designed to increase accessibility through the natural and artificial lumens within the human body.
Bargellini’s primary clinical and scientific focus is on oncologic imaging and interventional oncology, with reference to liver imaging and liver tumors’ loco-regional and systemic therapies.
“It is encouraging that leading interventional radiologists continue to join Microbot as it embarks on the steps towards the commercialization of the system,” Microbot Medical Chief Medical Officer Eyal Morag, M.D., said. “In addition to leveraging Dr. Bargellini’s expertise to achieve this goal, we also recognize that Italy represents an important and potentially large addressable market for the LIBERTY Robotic Surgical System. Dr. Bargellini is a potential future user, who we believe could support our entry into the Italian market upon regulatory clearance.”
Bargellini earned her medical degree from the University of Pisa, completed her radiology residency in Pisa and earned a master's degree in interventional radiology. From 2003 to 2022, she served as staff radiologist in the Interventional Radiology Department of Pisa University Hospital, then worked in the Interventional Radiology Unit of Florence University Hospital and just recently moved to Turin at Candiolo Cancer Institute. The main focus of her clinical and scientific work is oncologic imaging and interventional oncology, with particular reference to liver imaging and liver tumors' loco-regional and systemic therapies.
Bargellini is an Executive Committee member of the Italian Society of Radiology, a fellow of the European Society of Gastrointestinal and Abdominal Radiology and the Cardiovascular and Interventional Radiology Society in Europe, and a member of the European Society of Radiology, European Society for the Study of the Liver, and International Liver Cancer Association. She serves as reviewer of several national and international journals and is an editorial board member of European Radiology and Cardiovascular and Interventional Radiology journals. Bargellini has authored and co-authored more than 100 articles in peer-review journals, is co-author of several book chapters, and has given over 300 invited lectures in national and international meetings.
“I believe it’s important to support technology that can advance medicine and improve patient outcomes, and having experienced the system first-hand, I am eager to lend my capabilities and contribute to the system’s success,” Bargellini stated. “Additionally, I believe the potential of the LIBERTY Robotic Surgical System to reduce the level of radiation exposure makes it possible for more women to pursue a career as interventional radiologists, while not potentially endangering their health and/or ability to have children.”
The LIBERTY Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain.
Microbot Medical Inc. is a pre-clinical medical device company specializing in transformational micro-robotic technologies designed to increase accessibility through the natural and artificial lumens within the human body.